Recommended

GSK appoints new CEO
New webinar | Addressing the time-to-result challenge posed by short shelf-life radiopharmaceuticals, register today
Genmab acquires biotech Merus for $8bn
US FDA licensing first for IL-23 inhibitor to treat paediatric psoriasis
Teva makes progress on API business divestment
Takeda to move away from cell therapy
news

CDMO delivers 4,000 doses of COVID-19 vaccine candidate for Phase II/III trial

27
SHARES

Advent announced it has manufactured and delivered the first 4,000 doses of the AZD1222 vaccine candidate for the University of Oxford clinical trial.

vial labelled 'COVID-19 Vaccine'

Advent, an Italian Contract Manufacturing Organization (CMO) has manufactured and delivered the first batch of ChAdOx1 nCoV-19 (now called AZD1222), a novel COVID-19 vaccine candidate, for Phase II/III clinical trial.

 

Reserve your FREE place

 


Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.

20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion

This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.

Key learning points:

  • Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
  • Learn about ITM’s implementation journey and considerations when evaluating the technology
  • Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).

Don’t miss your chance to learn from experts in the industry – Register for FREE

 

The COV002 trial is being undertaken by the University of Oxford, UK. The first batch included 4,000 doses of the vaccine.

The AZD1222 vaccine uses a non-replicating adenovirus vector with the addition of the SARS-CoV-2 Spike (S) protein. SARS-CoV-2 is the virus causing the COVID-19 pandemic.

According to the CMO, it manufactured the first batch of vaccine in just over a month from receiving the seed stock. This was done by rapidly devising a manufacturing process to produce 13,000 doses of the COVID-19 vaccine. The company said the rapid and reliable development of a large-scale manufacturing process was critical, as Phase I trials are already underway.

“Speed is of the essence when facing a new outbreak such as this unprecedented Covid-19 pandemic,” said Professor Sarah Gilbert of the University of Oxford’s Jenner Institute. “Advent has manufactured and delivered the vaccine very quickly, producing a clinical batch in just over one month since we provided the seed stock, enabling us to rapidly prepare for larger scale clinical trials.”

The University of Oxford is partnering with AstraZeneca for the development and potential large-scale distribution of the vaccine candidate.

University of Oxford and AstraZeneca sign deal to produce COVID-19 vaccine…

Share via
Share via